Efficacy of Bisphosphonates and Recombinant Parathyroid Hormone in Treatment of Osteoporosis in Pakistan

preprint OA: closed
View at publisher

Abstract

Background: ; Osteoporosis is one of such disease which causes bone mass reduction by decreased formation of new bones. Low bone mineral density is frequent factor for osteoporosis. Increased osteoclast life span and advanced osteocytes as well as osteoblasts apoptosis is well adopted pathophysiological mechanism for low bone mass. Women are more prone than man. Approximately 200 million women have osteoporosis worldwide. Objective; Therefore, this study is designed to compare efficacy of bisphosphonates and recombinant human Para-thyroid hormone in treatment of osteoporosis. Main outcome measures; The comparison of these two treatment strategies is based upon therapeutic effectiveness, cost of therapy and availability of the drugs. Methods; The total duration of study was 1 year and during the study period a total 60 samples were analyzed randomly. Data was collected using a well-designed questionnaire. Results; rhPTH increase bone mass density (BMD) by 8-9% while bisphosphonates and estrogen therapy increase BMD 3-5% during the same time period. Conclusion; The current study was conducted in local population so that we could offer them the test possible treatment among the two most common treatment therapies available for osteoporosis.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00